NASDAQ · KVUE
Consumer Defensive · Household & Personal Products
$17.92
Down-$0.02 (-0.08%)
Updated Sep 16, 2026, 4:49 PM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
KVUE closed at $17.92 after 20 trading sessions, down 4.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $17.93 | $17.9356 | $17.70 | $17.92 | 53.83M |
| Sep 14, 2026 | $17.91 | $18.20 | $17.87 | $17.91 | 40.65M |
| Sep 11, 2026 | $17.90 | $17.965 | $17.60 | $17.78 | 47.16M |
| Sep 10, 2026 | $17.75 | $17.9158 | $17.72 | $17.79 | 64.38M |
| Sep 9, 2026 | $18.23 | $18.23 | $17.67 | $17.75 | 24.49M |
| Sep 8, 2026 | $18.625 | $18.65 | $18.38 | $18.39 | 16.22M |
| Sep 4, 2026 | $18.85 | $18.98 | $18.69 | $18.74 | 26.86M |
| Sep 3, 2026 | $19.18 | $19.185 | $18.84 | $18.95 | 18.57M |
| Sep 2, 2026 | $18.76 | $19.14 | $18.75 | $19.13 | 19.69M |
| Sep 1, 2026 | $18.90 | $19.03 | $18.71 | $18.75 | 21.75M |
| Aug 31, 2026 | $19.05 | $19.10 | $18.825 | $18.88 | 27.07M |
| Aug 28, 2026 | $19.26 | $19.39 | $19.13 | $19.17 | 11.89M |
| Aug 27, 2026 | $19.04 | $19.2499 | $18.985 | $19.20 | 14.74M |
| Aug 26, 2026 | $19.42 | $19.47 | $19.21 | $19.22 | 25.4M |
| Aug 25, 2026 | $19.28 | $19.38 | $19.175 | $19.33 | 20.42M |
| Aug 24, 2026 | $19.10 | $19.56 | $19.10 | $19.43 | 16.1M |
| Aug 21, 2026 | $18.97 | $19.16 | $18.87 | $19.06 | 13.57M |
| Aug 20, 2026 | $19.04 | $19.16 | $18.87 | $18.93 | 17.71M |
| Aug 19, 2026 | $18.91 | $19.185 | $18.88 | $19.13 | 36.19M |
| Aug 18, 2026 | $19.00 | $19.1151 | $18.80 | $18.80 | 25.52M |
The latest Smart Investors Daily articles mentioning KVUE.
KVUE research
Company profile and research snapshot.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | UBS | Neutral | — |
| Jul 21, 2026 | Barclays | Equal-Weight | — |
| Jul 16, 2026 | UBS | Neutral | — |
| Apr 15, 2026 | Citigroup | Neutral | — |
| Apr 14, 2026 | Barclays | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
SUMMIT, N.J., September 10, 2026--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026.
Benzinga · Sep 9, 2026
https://www.reuters.com/business/healthcare-pharmaceuticals/tylenol-use-pregnancy-may-be-linked-with-uterus-ovary-changes-daughters-2026-09-09/
SeekingAlpha · Sep 8, 2026
Key contributors include Infineon Technologies, Teradyne and Walmart. Learn more about key detractors.
Yahoo · Aug 31, 2026
Deal skepticism and litigation fears still weigh on this consumer staples stalwart.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KVUE.
